Oncotelic Therapeutics, Inc. (OTLC) stock
OTLCOTCPharmaceutical PreparationsFiscal year ends December 31
$0.02+0.00 (+11.45%)
Close on Oct 19, 2026Market cap $8.66MP/E 0.0Yield –
Oncotelic Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Oncotelic Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2024 was $12.21K. For fiscal 2025 it was $4.36K, down 92.9% from the year before. Over ten years it grew -52.5% a year on average. The highest annual figure on record is $22.26M in fiscal 2009.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.36K | -92.9% |
| FY2023 | Dec 31, 2023 | $61.14K | -91.9% |
| FY2022 | Dec 31, 2022 | $756.91K | -79.3% |
| FY2021 | Dec 31, 2021 | $3.66M | -15.0% |
| FY2020 | Dec 31, 2020 | $4.30M | +213.6% |
| FY2019 | Dec 31, 2019 | $1.37M | +111.2% |
| FY2018 | Dec 31, 2018 | $649.76K | -93.8% |
| FY2017 | Dec 31, 2017 | $10.47M | +19.5% |
| FY2016 | Dec 31, 2016 | $8.76M | -3.5% |
| FY2015 | Dec 31, 2015 | $9.09M | +22.7% |
| FY2014 | Dec 31, 2014 | $7.41M | +103.7% |
| FY2013 | Dec 31, 2013 | $3.64M | +3.2% |
| FY2012 | Dec 31, 2012 | $3.52M | -33.4% |
| FY2011 | Dec 31, 2011 | $5.29M | -56.3% |
| FY2010 | Dec 31, 2010 | $12.11M | -45.6% |
| FY2009 | Dec 31, 2009 | $22.26M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $345 | -28.1% |
| Q1 FY2026 | Mar 31, 2026 | $795 | +215.5% |
| Q2 FY2025 | Jun 30, 2025 | $297 | -38.1% |
| Q1 FY2025 | Mar 31, 2025 | $297 | -97.3% |
| Q3 FY2024 | Sep 30, 2024 | $480 | -97.7% |
| Q2 FY2024 | Jun 30, 2024 | $252 | -99.6% |
| Q1 FY2024 | Mar 31, 2024 | $480 | -99.3% |
| Q4 FY2023 | Dec 31, 2023 | $11.00K | +546.8% |
| Q3 FY2023 | Sep 30, 2023 | $21.22K | -80.5% |
| Q1 FY2023 | Mar 31, 2023 | $65.92K | -88.6% |
| Q4 FY2022 | Dec 31, 2022 | $66.21K | -87.3% |
| Q3 FY2022 | Sep 30, 2022 | $1.70K | -99.7% |
| Q2 FY2022 | Jun 30, 2022 | $108.71K | -88.6% |
| Q1 FY2022 | Mar 31, 2022 | $580.30K | -62.7% |
| Q4 FY2021 | Dec 31, 2021 | $523.20K | -79.7% |
| Q3 FY2021 | Sep 30, 2021 | $621.93K | -33.6% |
| Q2 FY2021 | Jun 30, 2021 | $956.81K | +98.5% |
| Q1 FY2021 | Mar 31, 2021 | $1.56M | +398.9% |
| Q4 FY2020 | Dec 31, 2020 | $2.57M | +877.6% |
| Q3 FY2020 | Sep 30, 2020 | $936.20K | +172.3% |
| Q2 FY2020 | Jun 30, 2020 | $482.14K | +32.5% |
| Q1 FY2020 | Mar 31, 2020 | $312.00K | -22.9% |
| Q4 FY2019 | Dec 31, 2019 | $263.10K | -8.2% |
| Q3 FY2019 | Sep 30, 2019 | $343.79K | +160.9% |
| Q2 FY2019 | Jun 30, 2019 | $363.77K | +263.6% |
| Q1 FY2019 | Mar 31, 2019 | $404.85K | +79.9% |
| Q4 FY2018 | Dec 31, 2018 | $286.62K | -83.8% |
| Q3 FY2018 | Sep 30, 2018 | $131.75K | -95.3% |
| Q2 FY2018 | Jun 30, 2018 | $100.05K | -96.7% |
| Q1 FY2018 | Mar 31, 2018 | $225.00K | -92.1% |
| Q4 FY2017 | Dec 31, 2017 | $1.77M | -24.1% |
| Q3 FY2017 | Sep 30, 2017 | $2.83M | +36.5% |
| Q2 FY2017 | Jun 30, 2017 | $3.02M | +27.2% |
| Q1 FY2017 | Mar 31, 2017 | $2.85M | – |
| Q4 FY2016 | Dec 31, 2016 | $2.34M | – |
| Q3 FY2016 | Sep 30, 2016 | $2.08M | – |
| Q2 FY2016 | Jun 30, 2016 | $2.37M | – |
See a number that looks wrong?